Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419657 | 1.00 | SIRT5 (0.54) | SIRT5MMP3TDP1KDM4EALDH1A1 | |
| SCHEMBL29419659 | 1.00 | SIRT5 (0.54) | SIRT5MMP3TDP1KDM4EALDH1A1 | |
| SCHEMBL29742197 | 1.00 | SIRT5 (0.54) | SIRT5MMP3TDP1KDM4EALDH1A1 | |
| SCHEMBL30205674 | 0.94 | TDP1 (0.56) | SIRT5TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL29436139 | 0.94 | TDP1 (0.56) | SIRT5TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL1301777 | 0.93 | TDP1 (0.50) | SIRT5MMP3TDP1KDM4EALDH1A1 | |
| SCHEMBL30070627 | 0.93 | MMP3 (0.52) | SIRT5MMP3TDP1KDM4EALDH1A1 | |
| SCHEMBL30070636 | 0.91 | TDP1 (0.53) | MMP3TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL14856419 | 0.90 | CASP3 (0.55) | SIRT5TDP1KDM4EALDH1A1HPGD | |
| SCHEMBL29791072 | 0.89 | KDM4E (0.50) | SIRT5MMP3TDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048003-A1 | STABLE CYCLODEXTRIN FREE CARFILZOMIB FORMULATION | AMGEN INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4004548-B1 | METHODS OF TREATING AND DIAGNOSING LUNG CANCER | YEDA RES & DEV (IL) | 2026-01-14 | — | — | EP | disclosed |
| US-20250354993-A1 | METHODS OF TREATING AND DIAGNOSING LUNG CANCER | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-11-20 | — | — | US | disclosed |
| US-20250345384-A1 | STABLE CYCLODEXTRIN FREE CARFILZOMIB FORMULATION | AMGEN INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025080942-A9 | PROTEASOME INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN’S HOSPITAL, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-111344018-B | Carfilzomib polyethylene glycol Stable compositions of compounds | 美国安进公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250179031-A1 | PROTEASOME ENHANCERS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-20250177540-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250161238-A1 | NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity | SAHIN FIKRET (TR) | 2025-05-22 | — | — | US | disclosed |
| US-9441012-B2 | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | TRILLIUM THERAPEUTICS INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS INC (US) | 2016-06-16 | — | — | US | disclosed |
| EP-3021862-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | Onyx Therapeutics, Inc. (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-08-06 | — | — | US | disclosed |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | FLUORINOV PHARMA INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| EP-2885314-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | Fluorinov Pharma Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2015009888-A2 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | ONYX THERAPEUTICS, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014161072-A1 | Α-BORYL ISOCYANIDES, BOROPEPTIDES AND BORON HETEROCYCLES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014029022-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014026282-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | SLASSI ABDELMALIK (CA) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179031-A1 | PROTEASOME ENHANCERS AND USES THEREOF | PSME3, PSMG3, PSME1 | SIRT5 1773/4885MMP3 1213/4885TDP1 415/4885 |
| US-20250345384-A1 | STABLE CYCLODEXTRIN FREE CARFILZOMIB FORMULATION | CRBN, CSNK1A1, CSNK1A1L | SIRT5 3448/4885MMP3 4185/4885TDP1 2558/4885 |
| US-20260048003-A1 | STABLE CYCLODEXTRIN FREE CARFILZOMIB FORMULATION | CSNK1D, CRBN, CSNK1A1 | SIRT5 4208/4885MMP3 2200/4885TDP1 2161/4885 |
| US-20150218212-A1 | FLUORINATED EPOXYKETONE-BASED TETRAPEPTIDE COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMA1, PSMB1, PSMB11 | SIRT5 2956/4885MMP3 3323/4885TDP1 1405/4885 |
| US-20160166632-A1 | PEPTIDE EPOXYKETONE PROTEASOME INHIBITORS IN COMBINATION WITH PIM KINASE INHIBITORS FOR TREATMENT OF CANCERS | PIM1, PIM2, PIM3 | SIRT5 2568/4885MMP3 2580/4885TDP1 1524/4885 |
| US-20250177540-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | SIRT5 910/4885MMP3 1823/4885TDP1 3083/4885 |
| US-20150203534-A1 | FLUORINATED EPOXYKETONE-BASED COMPOUNDS AND USES THEREOF AS PROTEASOME INHIBITORS | PSMB5, PSMB1, PSMB7 | SIRT5 1804/4885MMP3 3871/4885TDP1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.